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Abstract
How a drug distributes within highly compartmentalized mammalian cells can affect both the
activity and pharmacokinetic behavior. Many commercially available drugs are considered to be
lysosomotropic, meaning they are extensively sequestered in lysosomes by an ion trapping-type
mechanism. Lysosomotropic drugs typically have a very large apparent volume of distribution and
a prolonged half-life in vivo, despite minimal association with adipose tissue. In this report we
tested the prediction that the accumulation of one drug (perpetrator) in lysosomes could influence
the accumulation of a secondarily administered one (victim), resulting in an intracellular
distribution-based drug interaction. To test this hypothesis cells were exposed to nine different
hydrophobic amine-containing drugs, which included imipramine, chlorpromazine and
amiodarone, at a 10 µM concentration for 24 to 48 hours. After exposure to the perpetrators the
cellular accumulation of LysoTracker Red (LTR), a model lysosomotropic probe, was evaluated
both quantitatively and microscopically. We found that all of the tested perpetrators caused a
significant increase in the cellular accumulation of LTR. Exposure of cells to imipramine caused
an increase in the cellular accumulation of other lysosomotropic probes and drugs including
LyosTracker Green, daunorubicin, propranolol and methylamine; however, imipramine did not
alter the cellular accumulation of non-lysosomotropic amine-containing molecules including
MitoTracker Red and sulforhodamine 101. In studies using ionophores to abolish intracellular pH
gradients we were able to resolve ion trapping-based cellular accumulation from residual pH-
gradient independent accumulation. Results from these evaluations in conjunction with lysosomal
pH measurements enabled us to estimate the relative aqueous volume of lysosomes of cells before
and after imipramine treatment. Our results suggest that imipramine exposure caused a 4-fold
expansion in the lysosomal volume, which provides the basis for the observed drug interaction.
The imipramine-induced lysosomal volume expansion was shown to be both time- and
temperature-dependent and reversed by exposing cells to hydroxypropyl-β-cyclodextrin, which
reduced lysosomal cholesterol burden. This suggests that the expansion of lysosomal volume
occurs secondary to perpetrator-induced elevations in lysosomal cholesterol content. In support of
this claim, the cellular accumulation of LTR was shown to be higher in cells isolated from patients
with Niemann-Pick Type C disease, which are known to hyper-accumulate cholesterol in
lysosomes.
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A common feature among the majority of currently marketed small molecular weight
therapeutics is the presence of a weakly basic amine functional group. The presence of this
group often results in intracellular accumulation of the drug within discrete acidic
subcellular compartments, most notably lysosomes. These compounds are often referred to
as lysosomotropic amines and accumulate in lysosomes by a mechanism known as pH
partitioning or ion trapping.1 At physiological pH these compounds are significantly
unionized and passively diffuse across the lipid bilayers of cellular organelles. Upon
entering the acidic environment of the lysosome these amines become predominately
ionized and therefore less able to efficiently diffuse out, resulting in pronounced
accumulation. Reaching concentrations within the lysosome several orders of magnitude
greater than that seen in the extracellular space, these agents are capable of causing various
physiological and morphological perturbations of the lysosomal apparatus.2
Drugs that are extensively sequestered in lysosomes have been reported to alter the
organelles structure and function in many ways.3–6 One effect that has garnered great
interest is the capacity of these drugs to inhibit lysosomal lipid metabolism.7 This effect is
most closely associated with a subgroup of lysosomotropic amine drugs known as cationic
amphiphilic drugs (CADs). These compounds are typically described as containing both a
hydrophobic and a hydrophilic domain (i.e., amphiphilic) with the hydrophobic domain
containing an aromatic ring or ring system and the hydrophilic domain containing an
ionizable amine functional group.8 At therapeutically relevant concentrations CADs have
been shown to cause the lysosomal accumulation of various lipid species, including
sphingomyelin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine,
lysobisphosphatidic acid and cholesterol.9–12 In fact, CADs are often used in cell culture
models to induce a lysosomal lipid storage disease phenotype similar to that seen in cells
isolated from patients with Niemann-Pick disease (NPD).13, 14 Interestingly, work in our lab
and in others have shown that in addition to the lysosomal accumulation of lipids in NPD
cells, these cells also hyperaccumulate amine-containing compounds, presumably in a
lysosomal system that has seen a vast expansion in its volume.15, 16 These observations
along with previous work that has related drug-induced lipidosis to the hyperaccumulation
of amine-containing drugs17, 18 led us to hypothesize that CADs, because of their ability to
mimic the NPD lipidosis phenotype, would also cause an increase in the cellular
accumulation of other amine-containing drugs in the lysosomal apparatus. Such an ability of
CADs to alter the cellular retention of a second drug further led us to speculate the potential
for a novel mechanism through which drug interactions of clinical relevance can occur at the
level of intracellular drug distribution.
Drug interactions typically result from the ability of one drug to alter the pharmacokinetic
properties of a second drug; that is the absorption, distribution, metabolism or excretion
(ADME) properties.19 The ability of these interactions to cause clinically relevant changes
in drug efficacy and/or toxicity has yielded a large body of research that seeks to elucidate
the various pathways through which drugs can interact within the complex biological matrix
of the human body. Although the majority of this work involves drug interactions occurring
through modulation of drug metabolizing enzymes20 or membrane drug transporters,21 there
has been an effort to describe how the propensity of amine-containing drugs to accumulate
in lysosomes can result in distribution-based drug interactions.22, 23 Because of their
tendency to accumulate in lysosomes and in lysosome-rich tissues,24 amine-containing
drugs often have a high apparent volume of distribution.25 Therefore, if factors, such as drug
co-administration, can influence the deposition of these amine-containing drugs into
lysosome-rich tissues then the distribution profile of these drugs could be significantly
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altered. Such deviations in the distribution profile of the drugs are expected to have
implications in drug efficacy or toxicity.
In this report we show that exposure to various CADs results in an increase in the cellular
accumulation of secondarily administered amine-containing drugs. This effect was found to
be specific to amine-containing compounds that are substrates for ion trapping-based
accumulation in lysosomes. Mechanistic studies reveal that CADs cause an increase in the
apparent lysosomal volume of cells in a time- and temperature-dependent manner, consistent
with an energy-dependent cellular remodeling process. Treatments known to reverse the
CAD-induced lipidosis prevent the apparent increase in lysosomal volume. Our results are
consistent with the hypothesis that CADs, through their ability to inhibit cellular lipid
metabolism, cause an expansion of the lysosomal compartment of cells resulting in the
increased cellular uptake of lysosomotropic amine compounds, thus revealing a novel
pathway for intracellular distribution-based pharmacokinetic drug interactions. Our results
suggest that the observed interaction is associated with the physicochemical properties of the
drugs involved and does not appear to be related to therapeutic classification.
EXPERIMENTAL SECTION
Cell Lines and Reagents
LysoTracker Red DND-99 (LTR), LysoTracker Green DND-26 (LTG), MitoTracker Red
FM, sulforhodamine 101, anionic 70,000 mol. wt. Oregon Green Dextran, Dulbecco’s
phosphate buffered saline (D-PBS) and Dulbecco’s modified Eagle’s medium (DMEM)
were purchased from Invitrogen (Carlsbad, CA). Daunorubicin was purchased from
Oakwood Products (West Columbia, SC). Nigericin, monensin, hydroxypropyl-β-
cyclodextrin (HPCD), propranolol, imipramine, concanamycin A, ammonium chloride,
haloperidol, risperidone, chlorpromazine, lidocaine, bupivacaine, amiodarone, and
verapamil were purchased from Sigma-Aldrich (St. Louis, MO). [3H]propranolol was
purchased from GE Healthcare (Waukesha, WI). Lipoprotein-depleted serum (LPDS) was
purchased from Millipore (Billerica, MA). Fetal bovine serum (FBS) was purchased from
Atlanta Biologicals (Lawrenceville, GA). Wild type (WT) human fibroblasts (catalogue #
CRL-2076) were purchased from ATCC (Manassas, VA). NPC1−/− (catalogue # GM03123)
and NPC2−/− (catalogue # GM18455) human fibroblasts were purchased from Coriell Cell
Repository (Camden, NJ). MDA-1986 squamous cell carcinoma cells from the laboratory of
Dr. M.S. Cohen at the University of Kansas Medical Center. All cell cultures were grown in
DMEM supplemented with 10% FBS and maintained at 37 °C and 5% CO2, all experiments
were carried out under these conditions unless otherwise stated. Cells were routinely
subcultured to maintain 60 to 80% confluency and experiments were carried out within 10
passages following removal from cryopreservation.
Drug Treatments
Cells were seeded onto multi-well polystyrene plates and allowed to attach overnight.
Imipramine and the other CADs were added at a concentration of 10 µM for 24 to 48 h,
unless otherwise specified. Lysosomal alkalinizing treatments, including; 30 µM
chloroquine, 10 mM ammonium chloride and 200 nM concanamycin A were applied for a
total drug treatment time of 2 h. Lysosomal pH knockdown experiments were conducted
using a 2 h treatment with the ionophores, 10 µM nigericin and 20 µM monensin. In the pH
dependent binding studies, cell growth medium was exchanged with a pH 5.0 buffered
solution containing 150 mM sodium chloride, 20 mM Mes, 5 mM potassium chloride and 1
mM magnesium sulfate prior to the addition of the ionophores. In the temperature
dependency study cells were either maintained in 37°C media or switched to 4°C media
followed by the addition of imipramine or vehicle alone (D-PBS). After 4 h at either 4°C or
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37°C, cells were washed three times with 37°C D-PBS and replaced with fresh 37°C growth
media containing 200 nM LTR without imipramine. In lipidosis-reversing treatments,
growth media was removed and replaced with either fresh growth media, fresh growth
media supplemented with 0.1% HPCD or growth media without FBS but supplemented with
3 mg/ml LPDS. After 24 h, either imipramine or vehicle alone was added to each treatment
group for an additional 24 h.
Cell Imaging Studies
Human fibroblasts were viewed using a Nikon Eclipse 80i epifluorescence microscope
equipped with a 40× (1.30 NA) oil immersion objective and the corresponding filter cube
that best matched the spectral properties of each fluorophore. Images were acquired using an
ORCA ER camera (Hamamatsu). Images were analyzed using Metamorph version 7.0
(Universal Imaging) and ImageJ (free online at rsbweb.nih.gov) software. Human fibroblasts
were grown on glass coverslips and following a 46 h treatment with 10 µM imipramine or
vehicle alone the indicated fluorophore was added for 2 h. Concentrations of 100 nM LTR, 1
µM LTG, 1 µM daunorubicin, 5 µM sulforhodamine 101 and 100 nM MitoTracker Red were
used. At the end of the 48 h treatment period cells were washed twice with 37°C D-PBS
rapidly and immediately mounted on glass microscopy slides for live-cell imaging. Images
of intact cells not exposed to fluorescent probe were acquired to account for potential
autofluorescence and used for background correction. Images were captured under identical
instrument settings (i.e., detector gain, illumination intensity, exposure time and
magnification) and were scaled identically to allow for direct comparison of fluorophore
accumulation and distribution.
Drug Accumulation Assays
Cells were exposed to the indicated compound for 2 h under normal growth conditions,
except in the temperature dependency study where a 30 min incubation was used to avoid
potential reversion of the CAD-induced phenotype. Fluorescent compound concentrations
used were identical to those used in the Cell Imaging Studies with the exception of LTR
which was used at 200 nM in most experiments. Propranolol was added at a concentration of
100 nM containing 10 nM [3H]propranolol and [14C]methylamine was added at a
concentration of 10 µM. Cells were then washed twice with 37°C D-PBS rapidly to prevent
loss of cell-associated compound by diffusion. Cells were lysed in either 0.1 M NaOH or
lysis buffer (50 mM tris base, 150 mM NaCl, 1% NP40 adjusted to pH 7.4). Lysed samples
were immediately measured using a Bio-Tek FL600 microplate fluorescence reader or a
Beckman LS 60001C liquid scintillation counter. Background signal contribution from non-
specific binding to the plate surface was subtracted from each measurement. Cell protein
content was measured using the BCA method, and fluorescence (RFU) or radioactivity
(DPM) counts were normalized to cellular protein and overall cellular accumulation was
expressed in counts per microgram of protein or as a percentage of vehicle-treated control
cells.
Drug Uptake and Normalized Release Studies
Cells pretreated with 10 µM imipramine or vehicle alone for 48 h were exposed to 100 nM
propranolol, containing 10 nM [3H]propranolol for various times up to 2 h. At the end of the
uptake period, drug containing media was removed and cells were washed twice rapidly
with 37°C D-PBS. Lysis buffer (pH 7.4, 50 mM tris base, 150 mM NaCl, 1% NP40) was
added to each well and incubated at 37°C for 5 min. Cell lysate was transferred to
ScintiVerse BD Cocktail (Fisher) for scintillation counting and measured for protein content
using the BCA method. In addition, a dose-titration experiment was conducted in
imipramine treated cells to establish a dose of propranolol necessary to give equivalent
cellular propranolol levels in vehicle-treated control and impramine treated cells for the
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normalized release study (data not shown). A dose of 74 nM propranolol was established
and the ratio of labeled to unlabeled propranolol was maintained.
Following a 46 h treatment with imipramine or vehicle alone, 100 nM propranolol was
added to vehicle-treated control cells and 74 nM propranolol was added to imipramine
treated cells, containing 10 nM [3H]propranolol and 7.4 nM [3H]propranolol, respectively.
Following a 2 h incubation, the media was removed and cells were washed once with 37°C
D-PBS. Fresh media without propranolol was added to the cells. Imipramine or vehicle
alone was maintained in the media through the entirety of the experiment. At set timepoints,
media was removed and transferred to scintillation fluid. Fresh media was added at each
timepoint up to 60 min. After the last timepoint, lysis buffer (pH 7.4, 50 mM tris base, 150
mM NaCl, 1% NP40) was added and incubated at 37°C for 5 min. Cell lysate was
transferred to scintillation fluid and the remaining cell associated [3H]propranolol was
measured along with cell protein content using the BCA method. [3H]propranolol in each
sample was measured using a Beckman LS 60001C liquid scintillation counter.
Radioactivity counts (DPM) were normalized to cellular protein content and plotted in
counts per microgram of protein as a function of time.
Lysosomal pH Measurements
The influence of imipramine treatment on lysosomal pH was measured using a previously
published protocol with slight modifications.26 Briefly, MDA-1986 cells were plated onto 8-
chamber glass microscope slides and allowed to adhere overnight. Following a 24 h
exposure to 10 µM imipramine or vehicle alone, growth media was replaced with phenol
red-free growth media containing 1 mg/ml anionic 70,000 mol. wt. Oregon Green Dextran.
Imipramine or vehicle alone was maintained in the media through the entirety of the
experiment. Cells were incubated for 2 h under normal growth conditions followed by
removal of the fluorescent dextran conjugate containing media. Cells were washed twice
with 37°C sterile D-PBS. Pre-warmed phenol red free growth media was added and cells
were incubated under normal growth conditions for 6 h to chase the dextran conjugated
probe into lysosomes. Cells were then washed twice with and then maintained in a pH 7.4
buffer containing 150 mM NaCl, 20 mM MES, 5 mM KCl and 1 mM MgSO4. Fluorescence
intensity was measured while exciting at wavelengths of 451 nm and 495 nm on a
microscope equipped with a Photon Technology International (Birmingham, NJ)
Ratiomaster excitation spectrofluoromoter, a D/F/TR multiple bandpass dichroic mirror, a
525/10 nm emission filter and a photomultiplier tube detector. Ratios of fluorescence
intensity emissions at 525/10 nm (RFU495 nm/ RFU451 nm) were used to calculate lysosomal
pH according to lysosomal pH calibration curves constructed in both imipramine treated and
vehicle-treated control cells (data not shown). Calibration curves were created by measuring
the fluorescence emission ratio of the dextran conjugated probe localized to lysosomes in
cells exposed to pH 4.0, 5.0, 5.5 and 6.0 buffer supplemented with 10 µM nigericin and 20
µM monensin, as established previously.27 A linear fit of the calibration curves allowed
calculation of the lysosomal pH from the resulting best fit line equation.
Lysosomal Volume Calculations
The amount of LTR accumulated in cells by ion trapping-based accumulation in lysosomes
was determined in vehicle-treated control cells and cells pretreated with 10 µM imipramine
for 24h using eq. 1 where Dlys represents the amount of LTR accumulated in cells by ion
trapping, Dtotal represents the amount of LTR that accumulates under normal growth
conditions and Dnig/mon represents the amount of LTR that accumulates in cells following
disruption of intracellular pH gradients with the ionphores nigericin and monensin.
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In eq. 2 the fold change in ion trapping-based accumulation of LTR following treatment
with imipramine (ΔDlys) is directly related to changes in both lysosomal volume (ΔVlys)
and lysosomal concentrations of LTR (Δ[D]lys).
(2)
Eq.3 was derived by de Duve (1974) in his original work detailing the ion trapping theory
for weak base accumulation in lysosomes. The equation simply states that for a weakly basic
compound, such as LTR, the concentration in lysosomes ([D]lys) relative to the extracellular
space ([D]ext) is approximately equal to the ratio of the hydrogen ion concentration in the
lysosome ([H+]lys) compared to the extracellular space ([H+]ext).
(3)
Rearrangement of eq. 3 yields eq. 4. Assuming that in our experimental model the
concentration of LTR in the extracellular matrix and the extracellular pH are held constant,
the relationship between changes in lysosomal LTR concentrations and lysosomal pH can be
described by eq. 5. It can therefore be stated that changes in the lysosomal concentration of




Substituting eq. 5 into eq. 2 yields eq.6, which relates changes in LTR ion trapping in
lysosomes to changes in lysosomal pH and/or lysosomal volume.
(6)
Direct measurements of lysosomal pH and ion trapping-based accumulation of LTR in
vehicle-treated control and imipramine treated cells allowed for an approximation of the
relative lysosomal volume change resulting from imipramine treatment.
RESULTS
The ability of CADs to induce a generalized lipidosis in cultured cells and in vivo has been
extensively studied yet there remains little consensus regarding the therapeutic and/or
toxicological ramifications of it. In this report we examine how the CAD-induced lipidosis
influences the intracellular accumulation of amine-containing drugs that are substrates for
ion trapping-based accumulation. The observation that substrates for ion trapping
hyperaccumulate in cells with functional mutations in the Niemann Pick C1 protein led us to
hypothesize that exposure of cells to therapeutic agents that are known to induce a Niemann
Pick C1 mutation phenotype would also cause the hyperaccumulation of amines. If correct,
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this hypothesis would provide the foundation for a therapeutically important consequence of
CAD-induced lipidosis in the form of a distribution-based drug interaction pathway.
CAD Exposure and the Accumulation of Lysosomotropic Amine-Containing Compounds
We first set out to test if CADs could increase the lysosomal and cellular accumulation of
drugs or drug-like small molecules that are substrates for ion trapping-based accumulation in
lysosomes. Imipramine, a prototypical CAD that belongs to the tricyclic antidepressant class
of therapeutics, was exposed to human fibroblasts at a concentration of 10 µM for 48 h.
Cells were subsequently exposed to two well-documented substrates for ion trapping-based
accumulation in lysosomes, namely LysoTracker Red (LTR) and LysoTracker Green (LTG).
As previously reported28, 29 both probes have a punctate intracellular distribution indicative
of lysosomal sequestration (Figure 1A). Interestingly, cells that were pretreated with
imipramine consistently appeared to accumulate significantly more LTR and LTG relative to
vehicle-treated control cells. Quantitative measurements of total cellular accumulation of
these amine-containing compounds also showed an increase following imipramine treatment
(Figure 1B), thus supporting the microscopic observations. This CAD-induced phenotype
was also observed with the weakly basic anticancer agent daunorubicin (Figure 1) and the β-
adrenergic receptor antagonist propranolol (data not shown), both of which have been shown
to accumulate in lysosomes through an ion trapping-based mechanism.30, 31
It is possible that imipramine could enhance the cellular accumulation of the previously
tested amines according to a mechanism that is unrelated to their ion trapping-based
accumulation. Specifically, CAD treatment could theoretically expand the number of lipid
binding sites associated with the cell and therefore increase total cellular uptake of drugs. In
addition, the CADs could alter the intrinsic permeability of the plasma membrane of cells to
drugs in such a way that the total cellular accumulation of the drug is increased in the
presence of imipramine. In an effort to rule out these possibilities we tested if imipramine
pretreatment could increase the cellular accumulation of amines that are not substrates for
ion trapping in lysosomes. Specifically, sulforhodamine 101 and MitoTracker Red are low-
molecular weight, amine-containing compounds that are not substrates for ion trapping in
lysosomes.30, 32 We found that both of these non-lysosomotropic amines had no apparent
differences in cellular accumulation and distribution regardless of imipramine pretreatment
(Figure 1). Visual observations made using fluorescence microscopy (Figure 1A) were
supported by quantitative measurements (Figure 1B).
To further confirm that the CAD-induced enhancement in amine accumulation was indeed
reliant on intracellular pH gradients (i.e., lysosome-to-cytosol) we evaluated the cellular
accumulation of LTR in cells that were pretreated with the ionophores nigericin and
monensin. When treated with ionophores the pH of all cellular compartments are equal to
that of the cell culture medium. Under these conditions no intracellular pH gradients exist
and therefore no ion trapping-based accumulation can theoretically occur. We treated both
vehicle-treated control cells and cells pretreated with imipramine with the ionophores and
evaluated differences in LTR uptake. Interestingly, treatment of cells with ionophores under
normal pH conditions (i.e., pH 7.3) negated any CAD-induced enhancements in LTR
accumulation (Figure 2). These results suggest that the CAD-induced enhancement in LTR
accumulation is dependent upon ion trapping and cannot simply be attributed to enhanced
binding sites or changes in membrane permeability in CAD treated cells. In addition, to
address the possibility that amine-containing compounds accumulate through pH dependent
binding, which may be predicted to occur in the acidic lysosome, we measured the cellular
accumulation of LTR in vehicle-treated and imipramine-treated cells that were exposed to
ionophores in a pH 5.0 buffered solution (Figure 2). The failure of imipramine to increase
the cellular accumulation of LTR suggests that the observed hyperaccumulation does not
occur through the accumulation of pH-dependent binding sites that may be predicted with
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the accumulation of lysosomal phospholipids. The CAD-induced hyperaccumulation of
propranolol was also found to be reversed by the disruption of intracellular pH gradients
(data not shown). Further studies found that imipramine causes a dramatic increase in the
accumulation of the hydrophilic marker of aqueous lysosomal volume, methylamine
(Supplemental Figure 1), which would not be predicted to be a substrate for phospholipid
binding based on its hydrophilicity33 and has been previously used to indirectly measure the
aqueous lysosomal storage volume of cells.16, 34 Together, these results suggest that
accumulation of the amine-containing compounds isn’t caused by the binding to
accumulated drug-binding sites, such as phospholipids, but rather suggests that it results
from enhanced ion trapping in an expanded lysosomal compartment.
Imipramine is proposed to work by inhibiting the transporter-mediated uptake of
neurotransmitters in neuronal cells.35 Considering that the cells used for these evaluations
are non-neuronal, it is unlikely that the effect imipramine is having on lysosomes is directly
related to its therapeutic activity. Instead, we hypothesize that it is the physicochemical
properties of the drug that determine whether or not it perpetrates an interaction. To test this,
we examined the propensity of a series of eight drugs with variable therapeutic classification
but with similar cationic amphiphilic properties to imipramine to affect LTR accumulation.
The cationic amphiphilic properties are defined by the presence of a weakly basic, ionizable
amine (i.e., pKa) and the hydrophobicity of the compound (i.e., logP).36 The test drugs have
amine functional groups with predicted pKa values between 7.8 and 9.7 and are relatively
lipophilic with predicted logP values between 2.5 and 7.8. The structure and predicted
physichochemical properties (i.e., pKa and logP) of each drug is provided in Figure 3.
Structurally, all of the tested drugs can be described as containing a hydrophobic aromatic
ring or ring system spatially separated from an ionizable secondary or tertiary amine.
Interestingly, all of the CADs regardless of their therapeutic application caused a significant
increase in the cellular accumulation of LTR (Figure 4). These results confirm that the
physicochemical properties of the drug, not the therapeutic classification, drive the
propensity for this observed interaction.
Studies on the Mechanism of Enhanced Accumulation of Amine-Containing Compounds
Having established that CADs cause an increase in ion trapping-based drug accumulation
we further examined the potential basis for this. To narrow down the possible mechanisms
responsible we sought to determine whether CADs increased drug accumulation through an
increase in uptake or a decrease in release. Lysosomtropic compounds have a complicated
release mechanism, including the potential for vesicle-mediated efflux,37, 38 transporter
mediated efflux39 and simple passive diffusion40. We reasoned that increases in drug uptake
following CAD exposure would be indicative of an increase in the capacity of the cell to ion
trap the drug in lysosomes, either through a change in the pH or volume of the lysosomal
system. Decreases in drug release following CAD exposure would be indicative of either
inhibition of transporter-mediated or vesicle-mediated drug efflux. To display the
therapeutic relevance of this interaction pathway we chose to use the commonly prescribed
β-adrenergic antagonist propranolol, because it is a well-established substrate for ion
trapping-based accumulation.31 We found that imipramine treatment causes a profound
increase in propranolol uptake in fibroblasts (Figure 5A), but shows no effect on the
normalized propranolol release (Figure 5B). A normalized release profile was constructed to
allow direct comparison in the release profiles and was performed by reducing the
propranolol dose in the imipramine-treated cells. An uptake and normalized release study
was also conducted using LTG in place of propranolol in MDA-1986 cells and yielded
similar results (Supplemental Figure 2). These results indicate that CADs increase the
uptake of drugs that accumulate by ion trapping without significantly influencing release.
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Based on the theory of ion trapping described by de Duve, the extent of lysosomal
accumulation depends on the physicochemical properties of the drug (i.e., pKa and
membrane permeability properties), as well as, the properties of the lysosomal system, such
as pH and volume.1 Since the inherent physicochemical properties of the drug are not
influenced by CAD pretreatment we must assume that the properties of the lysosomes are.
The increased ion trapping capacity of cells would presumably result from a decrease in
lysosomal pH, an increase in the lysosomal volume or a mixture of the two effects.
Therefore we measured the effect of imipramine treatment on lysosomal pH and found that
exposure to 10 µM imipramine for 24 h resulted in no significant change in lysosomal pH
(pH 5.0 ± 0.9), as compared to vehicle-treated control cells (pH 4.9 ± 0.2) (Supplemental
Figure 3). The lack of a decrease in lysosomal pH following CAD treatment suggests that
CADs are causing an expansion of the volume of the lysosomal compartment. The steady-
state volume of lysosomes is a function of membrane fusion and fission events that facilitate
the biogenesis and depletion of lysosomes, respectively. Assuming that CADs interfere with
one or both of these processes, the effect of CADs should be both time- and temperature-
dependent. To test this possibility we incubated cells with 10 µM imipramine for varying
amounts of time and measured the impact on LTR accumulation. We found that the CAD-
induced enhancement in LTR accumulation was a progressive process with enhanced
accumulation minimal at early incubation times and maximal after approximately 10 to 15 h
of exposure (Figure 6A). Moreover, we found that incubation of cells with 10 µM
imipramine for 4 h failed to enhance the accumulation of LTR unless the temperature of the
incubation was maintained at 37°C. Cells incubated with or without CAD at 4°C for 4 h
showed no differences in LTR accumulation at 37°C as compared to cells maintained at
37°C throughout the treatment period (Figure 6B). These results are important since they are
consistent with the notion that CADs interfere with normal fusion and/or fission events that
dictate the steady-state volume of lysosomes.
As previously stated the cellular accumulation of LTR and other weakly basic amine-
containing compounds in lysosomes by ion trapping depends on both the pH and volume of
the lysosomal compartment. Therefore, the change in the volume of the lysosomal
compartment following imipramine treatment can be approximated if both lysosomal pH
and the amount of amine accumulated by ion trapping are known. Having measured
lysosomal pH changes after a 24 h exposure to imipramine (Supplemental Figure 3) we then
sought to measure the amount of LTR retained in cells by ion trapping in lysosomes under
the same treatment conditions. The amount of LTR accumulated in vehicle and imipramine
treated MDA-1986 cells by ion trapping-based accumulation in lysosomes was measured.
The ion trapping-based accumulation of LTR was determined by measuring the amount of
LTR accumulated in cells with a normal lysosome-to-cytosol pH gradient and those where
the pH gradient was eliminated by ionophore treatment. The difference in these values is
expected to represent the amount of LTR that accumulates by ion trapping in lysosomes. It
was found that cells treated with imipramine had a significantly elevated capacity to
accumulate LTR by ion trapping (Figure 7). Using the equations provided in the
Experimental section along with the lysosomal pH measurements and amount of LTR
accumulated by ion trapping for vehicle and imipramine treated cells an approximately 4-
fold increase in the lysosomal volume was determined to occur following a 24 h exposure of
MDA-1986 cells to 10 µM imipramine.
A comparison of LTR accumulation in wild type (WT) human fibroblasts with or without
imipramine treatment with human fibroblasts from NPD patients with loss-of-function
mutations in either the Niemann-Pick type C1 (NPC1) or Niemann-Pick type C2 (NPC2)
protein revealed that imipramine causes an increase in LTR accumulation similar to that
seen in cells isolated from NPD patients (Supplemental Figure 4). The possibility that the
cellular accumulation of cholesterol was contributing to the observed expansion of the
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lysosomal compartment was suggested by studies that found a reduction in LTR
accumulation in fibroblasts with mutations in NPC1 or NPC2 that were grown in
lipoprotein-depleted media (Supplemental Figure 5). Both treatment with 0.1% HPCD41 and
growth in lipoprotein-depleted media42 have been shown to at least partially reverse the
lipidosis observed in NPD fibroblasts. Therefore, we evaluated that ability of these
treatments to prevent the enhanced cellular accumulation of LTR observed following
imipramine treatment. We found that both lipidosis reversing treatments significantly
reduced LTR accumulation in imipramine treated cells (Figure 8). Therefore, it appears that
the increase in lysosomotropic amine retention following imipramine treatment is directly
related to the ability of imipramine to inhibit normal cholesterol clearance from late
endocytic compartments.
DISCUSSION
Similar to previous observations in lysosomal lipid storage disease cells, prolonged exposure
to lipidosis-inducing CADs caused a pronounced hyperaccumulation of amine-containing
compounds that are substrates for lysosomal ion trapping.15, 16, 37 Imipramine was found to
specifically increase the punctate vesicular staining and cellular accumulation of amine-
containing compounds that are substrates for ion trapping-based accumulation in lysosomes
but had no impact on the cellular accumulation of molecules that are not substrates (Figure
1). These results are suggestive of an increase in the ability of cells to accumulate amine-
containing drugs in lysosomal structures following imipramine exposure and argue against a
non-specific increase in cellular amine accumulation by increasing membrane permeability
or by increasing the non-specific cellular binding sites for any amine-containing compounds.
Initial studies were conducted using a human fibroblast cell line. Their outstretched cellular
morphology is conducive to microscopic evaluation, thus allowing greater visualization of
intracellular fluorescent probe distribution. In addition, it allowed for comparisons between
the CAD-induced phenotype and that observed in fibroblasts obtained from NPC disease
patients. The similarity between the distribution and accumulation of LTR in NPC disease
and CAD-treated fibroblasts was notable as can be seen by the TOC Figure and
Supplemental Figure 4. A 48 h CAD-treatment was initially chosen based on previous
studies showing a significant time-dependent induction of the lipidosis in human fibroblasts
that is most pronounced at this time point.43 Subsequent studies sought to illustrate that our
findings are not specific to one cell type, but instead are representative of cells regardless of
their source. The squamous cell carcinoma cell line MDA-1986 was chosen for this purpose.
The high proliferation rate of these cells allowed for rapid growth in culture which made
them preferable for high throughput analysis. Therefore, multiple evaluations were
undertaken using this cell line including the time-dependency of the CAD-induced increase
in LTR accumulation. It was found that maximal response was achieved within 24 hours of
drug exposure (Figure 6A). Therefore, subsequent experiments conducted in this cell line
were carried out using the optimized 24 h drug treatment, which was also found to be
adequate in the fibroblast cell line (Supplemental Figure 4). A 24 h imipramine treatment
was used in the determination of lysosomal ion trapping-based accumulation of LTR (Figure
7) and changes in lysosomal pH (Supplemental Figure 3) that were used to calculate changes
in apparent lysosomal volume.
In these studies, a variety of lysosomotropic amine compounds were used to probe for this
drug interaction pathway, including: LTR, LTG, daunorubicin, propranolol and
methylamine. The diversity of compounds used was to ultimately illustrate the broad
implications of this observed phenomenon. Not only did this work illustrate the capacity of
CAD treatment to affect the cellular accumulation of model lysosomotropic probes, like
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LTR and LTG, but it also showed that it had implications for therapeutic compounds, such
as daunorubicin and propranolol.
Because imipramine served as a model CAD, we wanted to be sure that its effect was
reflective of its cationic amphiphilic properties and not some other innate pharmacological
activity. Therefore, we tested eight other known CADs from a variety of pharmacological
classes for their ability to influence cellular accumulation of LTR and found that they all
significantly enhance LTR accumulation (Figure 4). The ability of CADs to increase the
cellular accumulation of lysosomotropic amine drugs illustrates a novel pathway through
which drug co-administration can lead to a distribution-based pharmacokinetic drug
interaction. Although a comprehensive structure activity relationship was not evaluated, the
series of tested CADs that were capable of causing a significant expansion of the lysosomal
volume were characterized as cationic, with predicted pKa values between 7.8 and 9.7, as
well as, lipophilic with a predicted logP between 2.5 and 7.8 (Figure 3).
The observed increase in amine-containing drug accumulation following CAD treatment
would at first glance appear to directly contradict earlier work that has illustrated the
capacity of lysosomotropic amine drugs to inhibit the cellular uptake of each other by
competing for uptake into lysosomes.23, 24, 44–49 This competition was presumed to occur
through the ability of lysosomotropic amine drugs to buffer the lysosomal pH and inhibit the
lysosomal uptake of secondarily applied lysosomotropic amine drugs. We believe these
apparent discrepancies originate from differences in drug dosing and duration of exposure
leading to differential physiological effects on cells and the lysosomal system. These earlier
studies relied on short-term, high-dose drug treatments which are known to cause acute
lysosomal alkalinization and therefore reduced ion trapping of amines in lysosomes.49 These
experiments were also conducted in purified lysosomes where it is not clear if the V-ATPase
was fully active under the experimental conditions. Our studies relied on longer durations of
drug exposure in intact cells with relatively lower treatment doses which is more closely
associated with the induction of a cellular lipidosis.50–52 In fact, we carried out additional
experiments with treatments known to cause lysosomal alkalinization6, 53 by exposing cells
to either 30 µM chloroquine, 10 mM ammonium chloride or 200 nM of the vacuolar-type
H+-ATPase inhibitor concanamycin A, concurrent with the 2 h LTR accumulation assay
(Supplemental Figure 6). Ammonium chloride is a weak base that requires millimolar drug
concentrations to cause a significant alkalinization of lysosomes, whereas chloroquine is a
dibasic amine that is capable of causing a significant buffering of the lysosome at
concentrations in the micromolar range.4, 6, 54 All lysosomal alkalinizing treatments were
found to drastically decrease the cellular accumulation of LTR under these conditions. Thus,
our results don’t argue against previous observations of potential drug interactions occurring
through drug-induced lysosomal alkalinization, but offers an additional pathway through
which amine-containing drugs that accumulate in lysosomes can influence the
pharmacokinetic properties of each other depending on their physiological effect on the
lysosomal apparatus. Since the therapeutic concentrations of most CADs are well below the
concentrations necessary to cause lysosomal alkalinization and since most of the typical
CADs are used as chronic therapies we would argue that CAD-induced lipidosis is a more
likely clinical scenario than lysosomal alkalinization.
By enhancing the cellular retention of this secondarily applied drug, one would expect
changes in the drug’s pharmacokinetic profile, such as an increase in the drug’s volume of
distribution and half-life. Following the initial characterization of this novel drug interaction
pathway we set out to understand the mechanism through which CADs cause the increased
cellular accumulation of compounds that are substrates for ion trapping in lysosomes. We
found that imipramine’s ability to increase LTR accumulation was strongly dependent on
imipramine exposure time (Figure 6A). Long exposure times were found to be needed for
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the maximum observed effect (>15 hrs). In addition, we found at low temperature (4°C)
imipramine was unable to induce the cellular changes needed for the increased LTR
accumulation observed at the physiological temperature of 37°C (Figure 6B). Our results are
unable to rule out the possibility that a reduction in the cellular accumulation of imipramine
at 4°C is responsible for the observed temperature-dependency, but we believe that together
these results argue against the possibility that imipramine is in some way inhibiting an acute
cellular efflux pathway for LTR and is consistent with imipramine inducing an energy-
dependent cellular remodeling process that results in enhanced LTR accumulation.
The predominant mechanism for uptake of lysosomotropic amines, such as LTR, is thought
to be through ion trapping,1 but realizing that work in our lab and others have shown that
amines often accumulate in cells to a degree greater than that predicted by ion trapping alone
suggests the potential for other mechanisms of intracellular and intralysosomal
retention.31, 49, 55, 56 The observation that elimination of the lysosome-to-cytosol pH
gradient reversed the ability of imipramine to influence LTR accumulation suggested that
this remodeling process resulted in an increase in the lysosomal ion trapping capacity of
cells (Figure 2). A comparison of the amount of LTR accumulated in cells by ion trapping in
lysosomes in control cells and cells treated with imipramine showed a significant increase in
lysosomal ion trapping-based accumulation of LTR in imipramine treated cells (Figure 7).
The assumption that lysosomal pH dependent accumulation of LTR is solely mediated by
the ion trapping mechanism led us to speculate that imipramine can cause one of two effects,
1) increased lysosomal volume or 2) decreased lysosomal pH, either of which would
increase the amount of LTR accumulating in the cell by ion trapping in lysosomes. To
distinguish the two possibilities, measurements of lysosomal pH were undertaken and
showed a slight but insignificant increase in lysosomal pH following imipramine treatment
(Supplemental Figure 3). Therefore we concluded that imipramine causes the increased
cellular accumulation of LTR by causing an expansion of the lysosomal volume, but
because definitive lysosomal volume measurements were not undertaken we have denoted
this change as an increase in the apparent lysosomal volume. These observations were
consistent with our microscopy studies that suggested an increase in the vesicular volume
that stained with the various lysosomotropic dyes (Figure 1).
A rather simple relationship is predicted to exist between the amount of drugs in lysosomes
sequestered by ion trapping, lysosomal volume and lysosomal pH. Therefore, measurement
of the effect of imipramine on the ion trapping-based accumulation of an LTR (Figure 7)
and lysosomal pH (Supplemental Figure 3) allows for an approximation of the imipramine-
induced expansion of the lysosomal volume. The equations for these simple relationships are
detailed in the Experimental section. Using the data collected in MDA-1986 cells following
a 24 h exposure to 10 µM imipramine we found an approximately 3-fold increase in the
steady state accumulation of LTR by ion trapping in lysosomes and a 0.1 unit increase in the
lysosomal pH. Together, these results would predict an approximately 4-fold increase in
lysosomal volume in the imipramine treated cells.
In order to assess if imipramine’s mechanism of increasing amine-drug accumulation was
through a decrease in lysosomotropic amine efflux kinetic measurements of both
lysosomotropic amine uptake and release were undertaken. Using two model lysosomotropic
amine compounds, LTG (Supplemental Figure 2) and propranolol (Figure 5), we found that
imipramine treatment doesn’t inhibit lysosomotropic amine efflux but rather increases
uptake. These results suggest that it is the enhanced steady-state volume of lysosomes
associated with imipramine exposure that contributes to increased accumulation.
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Based on our hypothesis that imipramine’s capacity to induce a cellular lipidosis is related to
its ability to cause an expansion of the apparent lysosomal volume and since the time-
dependency of this effect follows quite well to previous reports on the time dependency of
CAD induced lipid trafficking defects50, 51, 57 we tested the ability of lipidosis-correcting
treatments to prevent lysosomal volume expansion. We found that both, growth in
lipoprotein-depleted media and treatment with HPCD, as lipidosis reversing therapies,
prevented imipramine from increasing the cellular accumulation of our model
lysosomotropic amine probe, LTR (Figure 8). These results suggest that the lysosomal
volume expansion is secondary to the capacity of the perpetrator to inhibit the normal
trafficking of LDL-derived cholesterol out of lysosomes.
Our results are in agreement with recent work that has shown a progressive, non-steady state
accumulation profile for the phospholipidosis-inducing drug chloroquine.17 Similar to our
results these authors found that chloroquine at concentrations between 25 and 200 µM
induced the formation of an expanded acidic vesicular compartment that resulted in
enhanced cellular accumulation of the lipidosis-inducing drug. Their data shows a 10- to 30-
fold increase in vesicular volume with up to a 1 unit upward shift in the vesicular pH.
Although our CAD treatments showed a less pronounced increase in vesicular volume and
no significant increase in vesicular pH, we believe that such effects would be observed with
increasing drug concentrations.
Drug-drug interactions involving lysosomes examined in this work are projected to have
clinical significance. On a cellular level, we predict that drug-induced changes in the extent
of lysosomal sequestration can directly influence activity by altering the availability of the
drug to bind with intended extralysosomal targets. We also predict that this drug-interaction
could cause significant changes in the pharmacokinetic behavior of drugs. In an intact
animal the extensive sequestration of a drug in lysosomes is the cause for an extremely large
apparent volume of distribution and a prolonged elimination half-life. Accordingly, we
anticipate that pre-administration of a perpetrator in an animal could cause a significant
increase in the apparent volume of distribution and half-life of a subsequently administered
victim drug. This could have a significant impact on therapeutic outcomes, particularly for
those drugs that have a narrow therapeutic index.
It is interesting to entertain the likely possibility that many of the drugs that we have shown
to act as perpetrators in the interaction would also fall victim to it. In a clinical setting this
could result in volume of distribution and half-life parameters that appear to increase with
the time of administration. In support of this notion, kinetic studies of amiodarone in
humans indicated that half-life was 10–17 hours after a single i.v. dose and 8–21 days after
chronic administration.58
Collectively, this work illustrates an intracellular drug interaction pathway resulting from
the ability of CADs to cause an expansion of the apparent lysosomal volume of cells. The
perpetrator drug in such an interaction is the CAD, which causes an increase in the volume
of the lysosomal compartment. The victim drug would include any drug that accumulates in
lysosomes by the ion trapping-based mechanism, where lysosomal volume is an important
factor in determining total cellular drug accumulation. Therefore, victim drugs can include
both CAD and non-CAD lysosomotropic drugs. This lysosomal volume expansion was
found to be directly related to the CAD-induced cellular lipidosis and to result in the
increased cellular uptake of drugs that are substrates for ion trapping-based accumulation in
lysosomes. Our evaluations in this manuscript were performed using two different cell lines
from separate lineages. The fact that our results were consistently observed in these different
cell lines suggests that this drug-interaction could be universal and apply to any cells
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chronically exposed to CADs at relatively low concentrations. Further in vivo studies will
help reveal if this is the case.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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ABBREVIATIONS
CAD cationic amphiphilic drug
DMEM Dulbecco’s modified Eagle’s medium
D-PBS Dulbecco’s phosphate buffered saline




LTR LysoTracker Red DND-99
LTG LysoTracker Green DND-26
WT wild type
NPD Niemann-Pick disease
NPC1 Niemann-Pick type C1
NPC2 Niemann-Pick type C2
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Cellular accumulation of amine-containing compounds in human fibroblasts monitored by,
(A) epifluorescence microscopy or (B) quantification of total cellular accumulation,
following a 48 h treatment with vehicle alone or 10 µM imipramine. Scale bars represent 10
µm. Cellular accumulation of the compounds was measured in fluorescence units (RFU)
normalized to protein content and is represented as mean ± S.D from three independent
experimental evaluations (**, p < 0.01; ***, p < 0.001 by Student’s t test).
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LTR accumulation in MDA-1986 cells treated with vehicle alone or 10 µM imipramine
following disruption of the lysosome-to-cytosol pH gradient with ionophore treatment at
either, pH 7.3 or pH 5.0. Cellular accumulation of LTR was measured in fluorescence units
(RFU) normalized to protein content and is represented as the mean ± S.D from three
independent experimental evaluations.
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Structures of weakly basic drugs shown to cause a significant expansion in lysosomal
volume. The predicted pKa and LogP values for each of the drugs are listed (predictions
obtained using ChemAxon software available at http://www.chemicalize.org).
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LTR accumulation in MDA-1986 cells following a 24 h treatment with vehicle alone or
various CADs at a concentration of 10 µM. Cellular accumulation of LTR as a percentage of
vehicle-treated control cells is represented as mean ± S.D from three independent
experimental evaluations (***, p < 0.001 by Student’s t test).
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Propranolol (A) uptake and (B) normalized release profile in human fibroblasts following a
48 h treatment with vehicle alone or 10 µM imipramine. Cellular [3H]propranolol levels
were measured in radioactivity units (DPM) normalized to cellular protein content and is
represented as mean ± S.D from three independent experimental evaluations (**, p < 0.01
by Student’s t test).
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(A) Time- and (B) temperature-dependent accumulation of LTR in MDA-1986 cells
following treatment with vehicle alone (black bars) or 10 µM imipramine (white bars).
Cellular accumulation of LTR as a percentage of the vehicle-treated control cells is
represented as mean ± S.D from six independent experimental evaluations (**, p < 0.01;
***, p < .001 by Student’s t test).
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Ion trapping-based accumulation of LTR in MDA-1986 cells following a 24 h treatment
with vehicle alone or 10 µM imipramine. Following imipramine treatment, LTR
accumulation was measured with or without disruption of the lysosome-to-cytosol pH
gradient by ionophore treatment. The difference in the amount of LTR accumulated in cells
with and without an intact lysosome-to-cytosol pH gradient was determined to be the
amount of LTR accumulated by ion trapping. This value represents the amount of LTR
accumulated in cells through ion trapping in lysosomes. Cellular accumulation of LTR was
measured in fluorescence units (RFU) normalized to cellular protein content and expressed
as the mean ± S.D from three independent experimental evaluations (*, p < 0.05 by
Student’s t test).
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LTR accumulation in MDA-1986 cells following treatment with 10 µM imipramine (white
bars) with or without lipidosis-reversing treatments, as compared to vehicle-treated control
cells (black bar). Cellular accumulation of LTR as a percentage of the vehicle-treated
control cells is represented as mean ± S.D from three independent experimental evaluations
(***, p < .001 by Student’s t test).
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